Codexis extends collaboration with Teva

Published: 10-Dec-2009

Codexis has extended a licensing agreement signed with Teva Pharmaceutical Industries on 7 January. The new agreement covers three undisclosed pharmaceutical products.


Codexis has extended a licensing agreement signed with Teva Pharmaceutical Industries on 7 January. The new agreement covers three undisclosed pharmaceutical products.

Under the agreement generic drug manufacturer Teva will use Codexis biocatalysis technology for key process steps in the manufacture of the three products. Financial terms were not disclosed.

Codexis develops proprietary custom biocatalysts, and its technology is said to contribute to lower pharmaceutical process development and manufacturing costs.

"Expansion of our relationship with Teva from one to four products in under a year demonstrates the value of Codexis technology in today's competitive pharmaceuticals market," said Alan Shaw, president and chief executive of Codexis. "We are pleased to broaden our relationship with this major pharmaceuticals company."

See more

You may also like

Distribution

Teva Pharmaceuticals identifies risk to European medicine supply security in new research

Read more
The generic drug manufacturer warns that the European supply chain of critical generic medicines is not diversified, relying on a select few companies to distribute oncology, cardiology, antibiotic and mental health therapeutics

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Distribution

Teva Pharmaceuticals identifies risk to European medicine supply security in new research

The generic drug manufacturer warns that the European supply chain of critical generic medicines is not diversified, relying on a select few companies to distribute oncology, cardiology, antibiotic and mental health therapeutics
Distribution

Teva Pharmaceuticals, Klinge Pharma and Formycon join forces to commercialise Eylea biosimilar

FYB203, which will be marketed under the name AHZANTIVE®3 if approved by the EMA, will be commercialised by Teva Pharmaceuticals in the majority of Europe and Israel
Research & Development

Teva & Medincell release Phase III SOLARIS trial results for olanzapine in schizophrenic adults

The results indicate that Medincell's TEV-'749 subcutaneous extended release device for the administration of olanzapine in schizophrenic adults met primary and secondary endpoints
Manufacturing

Europe’s generic medicines are disappearing, study finds

Over a ten year period, the number of generic medicines withdrawn from the market increased by 12%
Research & Development

Teva UK and Closed Loop Medicine partner to advance personalised medicine development

SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Research & Development

Teva announces recruitment completion of Phase III clinical Study of mdc-TJK/Olanzapine LAI

Teva Pharmaceutical Industries announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase III clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference
Sustainability

Sandoz and Teva achieve independent certification for steps to minimise antimicrobial resistance risk

Certification demonstrates their commitment to protecting people and the planet
Subscribe now